OverviewSuggest Edit

Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. The Company believes its ability to identify novel drivers of disease, coupled with its proprietary library of novel and diverse chemical compounds, uniquely enables it to craft kinase therapies against new and difficult-to-drug targets.
TypePublic
Founded2011
HQCambridge, MA, US
Websiteblueprintmedicines.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Jan 2020)383(+77%)
Job Openings50
Revenue (FY, 2020)$793.7 M(+1094%)
Share Price (Sept 2021)$100
Cybersecurity ratingCMore

Key People/Management at Blueprint Medicines

Jeff Albers

Jeff Albers

CEO
Andrew Law

Andrew Law

Director, Corporate Director, Corporate Communications
Percy Carter

Percy Carter

Chief Scientific Officer
Charles Rowland

Charles Rowland

Director
Christoph Lengauer

Christoph Lengauer

Executive Vice President
Kate Haviland

Kate Haviland

Chief Operating Officer
Show more

Blueprint Medicines Office Locations

Blueprint Medicines has offices in Cambridge and Zug
Cambridge, MA, US (HQ)
45 Sidney St
Cambridge, MA, US
38 Sidney St #200
Zug, CH
Baarerstrasse 8
Show all (3)

Blueprint Medicines Financials and Metrics

Blueprint Medicines Revenue

Blueprint Medicines's revenue was reported to be $793.74 m in FY, 2020
USD

Revenue (Q1, 2021)

21.6m

Gross profit (Q1, 2021)

21.5m

Gross profit margin (Q1, 2021), %

99.5%

Net income (Q1, 2021)

(99.7m)

Market capitalization (14-Sept-2021)

5.8b

Closing stock price (14-Sept-2021)

100.0

Cash (31-Mar-2021)

698.0m

EV

5.2b
Blueprint Medicines's current market capitalization is $5.8 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

11.4m27.8m21.4m44.5m66.5m793.7m

Cost of goods sold

425.0k

Gross profit

793.3m

Gross profit Margin, %

100%
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

652.0k2.7m3.4m6.9m7.1m6.2m5.8m5.9m8.1m954.0k41.4m1.1m730.0k5.1m9.1m6.2m8.3m745.1m21.6m

Cost of goods sold

24.0k127.0k146.0k102.0k

Gross profit

6.1m8.2m745.0m21.5m

Gross profit Margin, %

100%98%100%100%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

162.7m52.1m400.3m68.1m113.9m684.6m

Accounts Receivable

61.6m663.0k7.1m

Prepaid Expenses

12.1m5.8m9.8m22.0m

Inventories

4.2m2.7m8.6m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

50.3m193.6m179.8m122.3m109.4m74.4m56.4m91.3m57.3m134.9m117.8m78.6m79.4m82.4m89.2m375.2m288.7m565.2m698.0m

Accounts Receivable

750.0k2.4m4.5m3.4m44.4m34.7m

Prepaid Expenses

1.3m5.8m6.2m1.9m2.2m3.4m4.7m7.2m6.2m8.4m8.8m6.0m10.7m14.8m15.2m10.1m17.9m17.4m25.9m

Inventories

2.7m4.4m5.6m16.0m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(52.8m)(72.5m)(148.1m)(236.6m)(347.7m)313.9m

Depreciation and Amortization

948.0k1.6m4.2m5.3m6.6m

Inventories

(1.5m)2.7m(6.7m)

Accounts Payable

1.4m2.2m1.5m(445.0k)1.4m(791.0k)
USDQ1, 2015

Financial Leverage

-0.6 x
Show all financial metrics

Blueprint Medicines Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Blueprint Medicines Online and Social Media Presence

Embed Graph

Blueprint Medicines Company Culture

  • Compensation

    A+

    100/100

Learn more on Comparably

Blueprint Medicines News and Updates

Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 2, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines' Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines' President, Research & Development, will participate virtually in a...

Blueprint Medicines Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass., July 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2021. "In the second quarter, we achieved one of our foundational corporate goals, securing U....

MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development

HOUSTON and CAMBRIDGE, Mass., July 28, 2021 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation (NASDAQ: BPMC) today announced a three-year strategic research collaboration focused on accelerating development of BLU-222, an investigational...

Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021

CAMBRIDGE, Mass., July 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, July 29, 2021 to report its second quarter 2021 financial results and provide a corporate...

Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021

CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced data from multiple poster presentations highlighting the breadth of the company's precision therapy pipeline at the virtual American Association for Cancer Research (AACR)...

Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results

CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020. "Last year was transformational for Blueprint Medicines, with four...
Show more

Blueprint Medicines Blogs

FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis

FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis Content Import Wed, 06/16/2021 - 15:50 FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis …

Joel Beatty, M.D., with Robert W. Baird

Joel Beatty, M.D., with Robert W. Baird John.Bissaillo… Fri, 06/04/2021 - 12:57 Joel Beatty, M.D. Robert W. Baird

Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

-- 88% ORR and median duration of response not reached in treatment-naïve patients with non-small cell lung cancer enrolled after expansion of trial inclusion criteria to include patients eligible for standard-of-care front-line therapy -- -- 53% ORR in heavily pre-treated patients with RET

Percy Carter, MBA, Ph.D.

Percy Carter, MBA, Ph.D. John.Bissaillo… Wed, 05/19/2021 - 10:50 Percy Carter, MBA, Ph.D. Chief Scientific Officer Percy brings more than 20 years of global leadership in pharmaceutical companies and industry experience. Prior to joining Blueprint Medicines, he se…

Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer

Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer Content Import Mon, 05/17/2021 - 08:03 Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer May 17, 2021 at 8:00 AM EDT This release is a backfill …

Blueprint Medicines Reports First Quarter 2021 Financial Results

Blueprint Medicines Reports First Quarter 2021 Financial Results Content Import Thu, 04/29/2021 - 07:05 Blueprint Medicines Reports First Quarter 2021 Financial Results April 29, 2021 at 7:00 AM EDT This release is a backfill from a News Wire Ea…
Show more

Blueprint Medicines Frequently Asked Questions

  • When was Blueprint Medicines founded?

    Blueprint Medicines was founded in 2011.

  • Who are Blueprint Medicines key executives?

    Blueprint Medicines's key executives are Jeff Albers, Andrew Law and Percy Carter.

  • How many employees does Blueprint Medicines have?

    Blueprint Medicines has 383 employees.

  • What is Blueprint Medicines revenue?

    Latest Blueprint Medicines annual revenue is $793.7 m.

  • What is Blueprint Medicines revenue per employee?

    Latest Blueprint Medicines revenue per employee is $2.1 m.

  • Who are Blueprint Medicines competitors?

    Competitors of Blueprint Medicines include AstraZeneca United States, Halozyme Therapeutics and Ohm Oncology.

  • Where is Blueprint Medicines headquarters?

    Blueprint Medicines headquarters is located at 45 Sidney St, Cambridge.

  • Where are Blueprint Medicines offices?

    Blueprint Medicines has offices in Cambridge and Zug.

  • How many offices does Blueprint Medicines have?

    Blueprint Medicines has 3 offices.